1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

Luis Paz‐Ares, Yasuhiro Gotô, W.D.T. Lim, Balázs Halmos, Byoung Chul Cho, Manuel Cobo, J.L. González-Larriba, C. Zhou, Ingel Demedts, Akin Atmaca, Sofia Baka, Bijoyesh Mookerjee, Socorro Portella, Zewen Zhu, Bharani Dharan, Martin Reck